Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Saved in:
| Title: | Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. |
|---|---|
| Authors: | Kahn AM; Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA., Perry CJ; Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA., Etts K; Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA., Kluger H; Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA., Sznol M; Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA. |
| Source: | The oncologist [Oncologist] 2024 Apr 04; Vol. 29 (4), pp. e507-e513. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyad300 |
